I suppose all of this should be taken in the context that PAB is a circa $20m enterprise value company.
We all know many biotechs that have a hell of a lot less but are prices at many multiples of what PAB is.
So this brings about the wretched inability of this company to deliver anywhere near the shareholder value that is warranted. If we take into account the Rights Issue debacle then one has to question what is going on behind the scenes?
when not if for pab now, page-23
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 21313437 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 7627380 | 5 |
View Market Depth
| Last trade - 14.40pm 24/12/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable
